|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-5.16/5.17
|
企业价值
23.42B
|
资产负债 |
每股账面净值
68.95
|
现金流量 |
现金流量率
--
|
损益表 |
收益
36.42M
|
每股收益
16.72
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/07 09:55 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |